Venous	venous	O	O
complications	complications	O	O
of	of	O	O
midazolam	midazolam	O	O
versus	versus	O	O
diazepam	diazepam	S_chemicals	O
.	.	O	O

Although	although	O	O
some	some	O	O
studies	studies	O	O
have	have	O	O
suggested	suggested	O	O
fewer	fewer	O	O
venous	venous	O	O
complications	complications	O	O
are	are	O	O
associated	associated	O	O
with	with	O	O
midazolam	midazolam	O	O
than	than	O	O
with	with	O	O
diazepam	diazepam	S_chemicals	O
for	for	O	O
endoscopic	endoscopic	O	O
procedures	procedures	O	O
,	,	O	O
this	this	O	O
variable	variable	O	O
has	has	O	O
not	not	O	O
been	been	O	O
well	well	O	O
documented	documented	O	O
.	.	O	O

We	we	O	O
prospectively	prospectively	O	O
evaluated	evaluated	O	O
the	the	O	O
incidence	incidence	O	O
of	of	O	O
venous	venous	O	O
complications	complications	O	O
after	after	O	O
intravenous	intravenous	O	O
injection	injection	O	O
of	of	O	O
diazepam	diazepam	S_chemicals	O
or	or	O	O
midazolam	midazolam	O	O
in	in	O	O
122	122	O	O
consecutive	consecutive	O	O
patients	patients	O	O
undergoing	undergoing	O	O
colonoscopy	colonoscopy	O	O
and	and	O	O
esophagogastroduodenoscopy	esophagogastroduodenoscopy	O	O
.	.	O	O

Overall	overall	O	O
,	,	O	O
venous	venous	O	O
complications	complications	O	O
were	were	O	O
more	more	O	O
frequent	frequent	O	O
with	with	O	O
diazepam	diazepam	S_chemicals	O
(	(	O	O
22	22	O	O
of	of	O	O
62	62	O	O
patients	patients	O	O
)	)	O	O
than	than	O	O
with	with	O	O
midazolam	midazolam	O	O
(	(	O	O
4	4	O	O
of	of	O	O
60	60	O	O
patients	patients	O	O
)	)	O	O
(	(	O	O
p	p	O	O
<	<	O	O
0.001	0.001	O	O
)	)	O	O
.	.	O	O

A	a	O	O
palpable	palpable	O	O
venous	venous	O	O
cord	cord	O	O
was	was	O	O
present	present	O	O
in	in	O	O
23	23	O	O
%	%	O	O
(	(	O	O
14	14	O	O
of	of	O	O
62	62	O	O
)	)	O	O
of	of	O	O
patients	patients	O	O
in	in	O	O
the	the	O	O
diazepam	diazepam	S_chemicals	O
group	group	O	O
,	,	O	O
compared	compared	O	O
with	with	O	O
2	2	O	O
%	%	O	O
(	(	B_chemicals	O
1	1	I_chemicals	O
of	of	O	O
60	60	O	O
patients	patients	O	O
)	)	O	O
in	in	O	O
the	the	O	O
midazolam	midazolam	O	O
group	group	O	O
(	(	O	O
p	p	O	O
<	<	O	O
0.002	0.002	O	O
)	)	O	O
.	.	O	O

Pain	pain	O	O
at	at	O	O
the	the	O	O
injection	injection	O	O
site	site	O	O
occurred	occurred	O	O
in	in	O	O
35	35	O	O
%	%	O	O
(	(	O	O
22	22	O	O
of	of	O	O
62	62	O	O
)	)	O	O
of	of	O	O
patients	patients	O	O
in	in	O	O
the	the	O	O
diazepam	diazepam	S_chemicals	O
group	group	O	O
compared	compared	O	O
with	with	O	O
7	7	O	O
%	%	O	O
(	(	O	O
4	4	O	O
of	of	O	O
60	60	O	O
patients	patients	O	O
)	)	O	O
in	in	O	O
the	the	O	O
midazolam	midazolam	O	O
group	group	O	O
(	(	O	O
p	p	O	O
<	<	O	O
0.001	0.001	O	O
)	)	O	O
.	.	O	O

Swelling	swelling	O	O
and	and	O	O
warmth	warmth	O	O
at	at	O	O
the	the	O	O
injection	injection	O	O
site	site	O	O
were	were	O	O
not	not	O	O
significantly	significantly	O	O
different	different	O	O
between	between	O	O
the	the	O	O
two	two	O	O
groups	groups	O	O
.	.	O	O

Smoking	smoking	O	O
,	,	O	O
nonsteroidal	nonsteroidal	B_chemicals	O
anti-inflammatory	anti-inflammatory	I_chemicals	O
drug	drug	S_chemicals	B_disease
use	use	O	I_disease
,	,	O	O
intravenous	intravenous	O	O
catheter	catheter	O	O
site	site	O	O
,	,	O	O
dwell	dwell	O	O
time	time	O	O
of	of	O	O
the	the	O	O
needle	needle	O	O
,	,	O	O
alcohol	alcohol	O	O
use	use	O	O
,	,	O	O
and	and	O	O
pain	pain	O	O
during	during	O	O
the	the	O	O
injection	injection	O	O
had	had	O	O
no	no	O	O
effect	effect	O	O
on	on	O	O
the	the	O	O
incidence	incidence	O	O
of	of	O	O
venous	venous	O	O
complications	complications	O	O
.	.	O	O

